Literature DB >> 23912673

Medication management of chronic heart failure in older adults.

Kannayiram Alagiakrishnan1, Maciej Banach, Linda G Jones, Ali Ahmed, Wilbert S Aronow.   

Abstract

Heart failure (HF) is a common problem in older adults. Individuals aged 65 years or older are at a higher risk for developing HF, especially diastolic HF or HF with preserved ejection fraction (HFpEF). HF can be seen in up to 20 % of adults aged 85 years or older. In contrast to middle-aged (40-64 years) HF patients, multiple cardiac, non-cardiac and geriatric syndrome co-morbidities are seen in elderly HF patients. Additionally, age-related changes in pharmacokinetics and pharmacodynamics influence medication therapy. Hence, the management of older patients with HF is challenging and treatment should be modified in the light of the above-mentioned conditions. This article discusses the current evidence for medication management in both systolic HF or HF with reduced ejection fraction (HFrEF) and HFpEF, noting, however, the limited data for HFpEF and HFrEF in those 80 years of age or older. The objective of this article is to discuss evidence-based and outcomes-driven pharmacologic management strategies for chronic HF in the older adults for whom functional and other patient-centered outcomes might be more than or as important as clinical outcomes. Optimal management would be expected to help to reduce illness burden, reduce mortality and hospitalizations, and improve function and quality of life.

Entities:  

Mesh:

Year:  2013        PMID: 23912673     DOI: 10.1007/s40266-013-0105-9

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  141 in total

1.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.

Authors:  Eric J Eichhorn; Michael J Domanski; Heidi Krause-Steinrauf; Michael R Bristow; Philip W Lavori
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

2.  Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure.

Authors:  Masayuki Yamaji; Takayoshi Tsutamoto; Chiho Kawahara; Keizo Nishiyama; Takashi Yamamoto; Masanori Fujii; Minoru Horie
Journal:  Am Heart J       Date:  2010-11       Impact factor: 4.749

3.  Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure.

Authors:  Bojan Vrtovec; Renata Okrajsek; Alenka Golicnik; Mateja Ferjan; Vito Starc; Branislav Radovancevic
Journal:  J Card Fail       Date:  2005-12       Impact factor: 5.712

4.  Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance.

Authors:  J F Setaro; B L Zaret; D S Schulman; H R Black; R Soufer
Journal:  Am J Cardiol       Date:  1990-10-15       Impact factor: 2.778

Review 5.  Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new.

Authors:  Jasmine A Talameh; Howard L McLeod; Kirkwood F Adams; J Herbert Patterson
Journal:  J Card Fail       Date:  2012-02-02       Impact factor: 5.712

6.  Diuretic use, progressive heart failure, and death in patients in the DIG study.

Authors:  Michael Domanski; Xin Tian; Mark Haigney; Bertram Pitt
Journal:  J Card Fail       Date:  2006-06       Impact factor: 5.712

Review 7.  Update on diastolic heart failure or heart failure with preserved ejection fraction in the older adults.

Authors:  Kannayiram Alagiakrishnan; Maciej Banach; Linda G Jones; Subrata Datta; Ali Ahmed; Wilbert S Aronow
Journal:  Ann Med       Date:  2012-03-13       Impact factor: 4.709

8.  Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II.

Authors:  Michel Komajda; Olivier Hanon; Matthias Hochadel; Jose Luis Lopez-Sendon; Ferenc Follath; Piotr Ponikowski; Veli-Pekka Harjola; Helmut Drexler; Kenneth Dickstein; Luigi Tavazzi; Markku Nieminen
Journal:  Eur Heart J       Date:  2008-12-23       Impact factor: 29.983

9.  Sildenafil and diastolic dysfunction after acute myocardial infarction in patients with preserved ejection fraction: the Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (SIDAMI) trial.

Authors:  Mads J Andersen; Mads Ersbøll; Anna Axelsson; Finn Gustafsson; Christian Hassager; Lars Køber; Barry A Borlaug; Søren Boesgaard; Lene T Skovgaard; Jacob E Møller
Journal:  Circulation       Date:  2013-02-13       Impact factor: 29.690

10.  Effect of atorvastatin in patients with chronic heart failure - insights from randomized clinical trials.

Authors:  Minwen Xu; Gaohui Yuan; Fanping Wei
Journal:  Arch Med Sci       Date:  2010-12-29       Impact factor: 3.318

View more
  7 in total

1.  Impact of Exercise Programs on Hospital Readmission Following Hospitalization for Heart Failure: A Systematic Review.

Authors:  Parag Goyal; Diana Delgado; Scott L Hummel; Kumar Dharmarajan
Journal:  Curr Cardiovasc Risk Rep       Date:  2016-09-09

2.  Pharmacotherapy Use in Older Patients With Heart Failure and Reduced Ejection Fraction After a Skilled Nursing Facility Stay.

Authors:  Lin Li; Bill M Jesdale; Anne Hume; Giovanni Gambassi; Robert J Goldberg; Kate L Lapane
Journal:  J Card Fail       Date:  2017-09-20       Impact factor: 5.712

3.  Clinical factors associated with early readmission among acutely decompensated heart failure patients.

Authors:  Bredy Pierre-Louis; Shareen Rodriques; Vanessa Gorospe; Achuta K Guddati; Wilbert S Aronow; Chul Ahn; Maurice Wright
Journal:  Arch Med Sci       Date:  2016-05-18       Impact factor: 3.318

4.  Heart failure in the diabetic population - pathophysiology, diagnosis and management.

Authors:  Jacek Kasznicki; Jozef Drzewoski
Journal:  Arch Med Sci       Date:  2014-06-27       Impact factor: 3.318

Review 5.  Lipid, blood pressure and kidney update 2013.

Authors:  Maciej Banach; Corina Serban; Wilbert S Aronow; Jacek Rysz; Simona Dragan; Edgar V Lerma; Mugurel Apetrii; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2014-02-27       Impact factor: 2.370

6.  Prognostic Impact of Statin Intensity in Heart Failure Patients With Ischemic Heart Disease: A Report From the CHART-2 (Chronic Heart Failure Registry and Analysis in the Tohoku District 2) Study.

Authors:  Takuya Oikawa; Yasuhiko Sakata; Kotaro Nochioka; Masanobu Miura; Kanako Tsuji; Takeo Onose; Ruri Abe; Shintaro Kasahara; Masayuki Sato; Takashi Shiroto; Jun Takahashi; Satoshi Miyata; Hiroaki Shimokawa
Journal:  J Am Heart Assoc       Date:  2018-03-14       Impact factor: 5.501

7.  Improved outcome with standardized plan for clinical management of acute decompensated chronic heart failure.

Authors:  Marie-Louise Edvinsson; Albin Stenberg; Karin Åström-Olsson
Journal:  J Geriatr Cardiol       Date:  2019-01       Impact factor: 3.327

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.